作者:Andrea Dalle Vedove、Francesca Zonta、Enrico Zanforlin、Nicola Demitri、Giovanni Ribaudo、Giulia Cazzanelli、Alberto Ongaro、Stefania Sarno、Giuseppe Zagotto、Roberto Battistutta、Maria Ruzzene、Graziano Lolli
DOI:10.1016/j.ejmech.2020.112267
日期:2020.6
Its inhibitor SRPIN803, based on a 6-methylene-5-imino-1,3,4-thiadiazolopyrimidin-7-one scaffold, showed notable specificity. Our synthesis of the initially proposed SRPIN803 resulted in its constitutional isomer SRPIN803-revised, where the 2-cyano-2-propenamide group does not cyclise and fuse to the thiadiazole ring. Its crystallographic structure in complex with CK2α identifies the structural determinants
蛋白激酶CK2维持癌症的生长,特别是在血液系统恶性肿瘤中。其抑制剂SRPIN803基于6-亚甲基-5-亚氨基-1,3,4-噻二唑并吡啶亚胺-7-7骨架,表现出显着的特异性。我们最初提出的SRPIN803的合成导致其结构异构体SRPIN803进行了修订,其中2-氰基-2-丙烯酰胺基团不环化并与噻二唑环融合。与CK2α配合形成的晶体结构确定了报道的特异性的结构决定因素。SRPIN803修订版探讨了CK2开放铰链构象,这种结构在激酶中极为罕见,并且也与该区域的侧链相互作用。它的优化产生了更有效的化合物4,该化合物抑制细胞内CK2,显着影响肿瘤细胞的活力,并在一组320种激酶上显示出显着的选择性。